COVID-19 Transmission and Morbidity in Malawi

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-75
SponsorBoston University

About this trial

SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the Americas. To identify what is different requires a better understanding of the underlying immunological substrate of the population, and how these factors affect susceptibility to infection, progression of symptoms, transmission, and responses to SARS-CoV-2 vaccination.

Study objectives

1. Determine the risk and predictors of infection and disease among contacts of SARS-CoV-2 infection subjects in Malawi 2. Determine whether innate immune responses lower the risk of SARS-CoV-2 infection and disease, and acquisition and duration of vaccine responses. 3. Assess whether alterations in innate immune responses relevant to SARS-CoV-2 are associated with malaria or intestinal parasite infections. 4. Assess the acquisition and longevity of antibodies (Ab) and cellular adaptive responses elicited by SARS-CoV-2 infection and vaccination. 5. Assess whether malaria and intestinal parasite infections, chronic/mild undernutrition, and anemia mediate alterations in Ab and other adaptive cellular responses to SARS-CoV-2 through innate immune responses or a different unknown mechanism.

Eligibility criteria

Qualifiers

Presents with symptoms of COVID-19 and has infection confirmed through RT-PCR or a rapid antigen test;

Aged 5 years to 75 years and plans to live in Blantyre, in the catchment area of the target research health centers for the following 6 months;

Confirmed SARS-CoV-2 infection and share a household with 1 or more individuals of eligible age;

Has not received a SARS-CoV-2 vaccine in the previous 3 months

Disqualifiers

Conditions that precludes from adherence to the visit schedule;

50% or more of household members decline to participate.

Pregnancy at the enrollment visit

Long term use of cotrimoxazole prophylaxis

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,500 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Boston University

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator

Kamuzu University of Health Sciences

Collaborator

Burnet Institute

Collaborator